Table 1.

FDA approved mAbs in autoimmune diseases.

Target and technology	Drug	FDA-approved diseases
Chimeric anti-CD20 mAb	Rituximab	Rheumatoid arthritis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Pemphigus
Humanized anti-CD20 mAb	Ocrelizumab	Relapsing and progressive multiple sclerosis
Fully human anti-CD20 mAb	Ofatumumab	Relapsing multiple sclerosis
Humanized anti-CD19 mAb	Inebilizumab	Neuromyelitis optica spectrum disorder
Fully human anti-BAFF mAb	Belimumab	SLE; Lupus nephritis